Efficacy and safety of CLSi017 in managing menopausal symptoms: A randomized, doubleblind, placebo-controlled clinical trial of Asparagus racemosus root extract
Planta Medica · 01.03.2026 · 92 (03) · 397
DOI: 10.1055/s-0045-1815399 ↗Kurz gefasst
Fachartikel in der Zeitschrift Planta Medica, erschienen am 01.03.2026. Verfasst von A Swaroop.
Abstract (Originalsprache)
Menopause is a significant transitional phase in womens’ lives characterized by hormonal fluctuations that often involve uncomfortable symptoms affecting quality of life. Though hormone replacement therapy may alleviate some issues, it is also associated with increased risk of cardiac events and some cancers [ 1 ]. Shatavari ( Asparagus racemosus) has been long utilized in traditional Ayurvedic medicine to support women’s reproductive health, though rigorous clinical evidence for its efficacy remains limited [ 2 ]. In this study, we evaluated standardized A. racemosus root extract (CLSi017) in improving menopausal symptoms across somatic, psychological, and urogenital domains. 60 healthy (pre-, peri-, and post-menopausal) women aged 40-55 years were recruited and randomized into 2 groups to receive daily doses of either 100 mg of placebo-brown rice starch or CLSi017-5% Shatavarin IV root extract (double-blinded administration). Menopausal symptoms were assessed at baseline (pre-treatment) and at 4- and 8-weeks (post-treatment) using the Menopause Rating Scale (MRS). Confirming successful randomization, both groups reported similar baseline MRS scores (~15 on a 44 point scale). However, post-treatment, the CLSi017 group demonstrated significant reduction in menopausal symptom severity at week 4 (43% decrease) and at week 8 (71% decrease, linear mixed model LMM analysis, p 90% improved at week 8). Adverse events were mild, transient, and comparable between groups, with gastrointestinal discomfort being the most common. These findings suggest that CLSi017 may represent a promising botanical alternative for women seeking non-hormonal approaches to manage menopausal symptoms. Publication History Article published online: 05 March 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Zitieren
APA
Swaroop, A. (2026). Efficacy and safety of CLSi017 in managing menopausal symptoms: A randomized, doubleblind, placebo-controlled clinical trial of Asparagus racemosus root extract. Planta Medica, 92(03), 397. https://doi.org/10.1055/s-0045-1815399
Vancouver
Swaroop A. Efficacy and safety of CLSi017 in managing menopausal symptoms: A randomized, doubleblind, placebo-controlled clinical trial of Asparagus racemosus root extract. Planta Medica. 2026;92(03):397. doi:10.1055/s-0045-1815399
BibTeX
@article{Swaroop2026,
author = {Swaroop, A},
title = {Efficacy and safety of CLSi017 in managing menopausal symptoms: A randomized, doubleblind, placebo-controlled clinical trial of Asparagus racemosus root extract},
journal = {Planta Medica},
year = {2026},
volume = {92},
number = {03},
pages = {397},
doi = {10.1055/s-0045-1815399}
}
EUVIMED